August 3, 2015 at 6:55 pm

Categories: News

BioStructures, LLC is pleased to report on its latest corporate landmark event…the company is announcing that it has reached a milestone of 4,000 implantations of Signafuse Bioactive Bone Graft Putty. In 2014 Signafuse was FDA 510(k) cleared as a bone void filler indicated for standalone use in posterolateral spine fusion procedures. According to the July 30, 2015 news release, Signafuse is “a moldable bone graft comprising a proprietary combination of patented bioactive glass particles and biphasic mineral granules suspended in a patented resorbable polymer carrier.”

Biostructures Chief Technology Officer John Brunelle, Ph.D., “Signafuse was intentionally designed to support the complex healing requirements of posterolateral spine fusion surgery, without the aid of autologous extenders or enhancers. Following a comprehensive evaluation of the best available bone graft technologies, published clinical data and surgeon feedback, paired with an intuitive understanding of the fusion healing environment, we conceived a composite bone graft that would thrive in the complex fusion healing environment.”


Jump to the article